Share ownership CSL Limited

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 10:40:28 13/03/2026 am IST			5-day change	1st Jan Change
141.03 ^AUD	-0.01%		-3.58%	-18.31%

11/03	ASX Midday Sector Update: Materials Stocks Advance, Health Care Sector Struggles	MT
11/03	CSL Shares Fall as It Enters Long-Term Agreement With Pan American Health Organization for Influenza Vaccines	MT

Share class: CSL Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	48,32,52,729	48,27,51,160 ( 99.9 %)	0	99.9 %

Major shareholders: CSL Limited

Name	Equities	%	Valuation
State Street Global Advisors Trust Co. 1.072 %	52,02,149	1.072 %	544 M $
Colonial First State Investments Ltd. 0.7203 %	34,94,546	0.7203 %	365 M $
Commonwealth Superannuation Corp. (Investment Management) 0.6933 %	33,63,436	0.6933 %	352 M $
Netwealth Investments Ltd. 0.689 %	33,42,620	0.689 %	350 M $
Australian Foundation Investment Co. Ltd. (Invt Mgmt) 0.5602 %	27,18,001	0.5602 %	284 M $
BetaShares Capital Ltd. 0.5508 %	26,72,331	0.5508 %	279 M $
Mutual Trust Pty Ltd. 0.2961 %	14,36,680	0.2961 %	150 M $
Argo Investments Ltd. (Investment Management) 0.2786 %	13,51,509	0.2786 %	141 M $
Pendal Group Ltd. (Investment Management) 0.2668 %	12,94,563	0.2668 %	135 M $
State Street Global Advisors Ltd. 0.1841 %	8,93,167	0.1841 %	93 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Domini Impact Investments LLC 0.003566 %	69,200	0.003566 %	4 M $
Yousif Capital Management LLC 0.001494 %	28,986	0.001494 %	2 M $
RhumbLine Advisers LP 0.001249 %	24,238	0.001249 %	1 M $
MBH Investment Fund Management Private Ltd. Co. 0.000311 %	6,026	0.000311 %	315 124 $
GAMMA Investing LLC 0.000095 %	1,836	0.000095 %	96 012 $
Salomon & Ludwin LLC 0.000046 %	894	0.000046 %	46 751 $
PNC Wealth Management LLC 0.000014 %	268	0.000014 %	14 015 $
Hantz Financial Services, Inc. 0.000004 %	72	0.000004 %	3 765 $
Signature Equity Partners LLC 0.000002 %	38	0.000002 %	1 987 $
IMA Advisory Services, Inc. 0.000001 %	20	0.000001 %	1 046 $

Breakdown by shareholder type

Institutional	7.53%
Individuals	0.06%
Unknown	92.41%

Based on 1000 largest holdings

Geographical origin of shareholders

Australia	5.13%
United States	1.29%
United Kingdom	0.27%
Sweden	0.15%
Hong Kong	0.13%
Netherlands	0.09%
Ireland	0.08%
Individuals	0.06%
New Zealand	0.05%
Norway	0.04%
Luxembourg	0.04%
Finland	0.04%
Germany	0.03%
Italy	0.02%
Switzerland	0.02%
Spain	0.02%
Canada	0.02%
Singapore	0.02%
Denmark	0.02%
Japan	0.02%
Austria	0.01%
France	0.01%
Indonesia	0.01%
South Africa	0.01%

Based on 1000 largest holdings

CSL Limited is an Australia-based biotechnology company. The Companyâ€™s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Companyâ€™s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Employees

29,904

Sector

Pharmaceuticals

Calendar

18/08 - Earnings release - Annual 2026

More about the company